Neuropsychiatrie symptoms caused by metloquine (report of several cases);A mefloquin okozta neuropszichiátriai tünetegyüttesek (néhány eset alapján)

Orvosi Hetilap

Volumn 146, Issue 3, 2005, Pages 133-136

  Murai, Zita ^a,b   Baran, Brigitta ^a   Tolna, Judit ^a   Szily, Erika ^a   Gazdag, Gábor ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Pszichiátriai es Addiktológiai Szakrendelo ^*  (Hungary)

Author keywords

Malaria; Mefloquine; Neuropsychiatric side effects; Profilaxis

Indexed keywords

MEFLOQUINE; ANTIMALARIAL AGENT;

ANAMNESIS; ARTICLE; CLINICAL FEATURE; DEPRESSION; DISEASE SEVERITY; DIZZINESS; HUMAN; MALAISE; OUTPATIENT CARE; PANIC; PSYCHOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SCREENING TEST; ADULT; CHEMICALLY INDUCED DISORDER; FEMALE; MALARIA; MALE; MENTAL DISEASE; METHODOLOGY; MIDDLE AGED; PRIMARY PREVENTION; TRAVEL;

ADULT; ANTIMALARIALS; DEPRESSION; FEMALE; HUMANS; MALARIA; MALE; MEFLOQUINE; MENTAL DISORDERS; MIDDLE AGED; PANIC DISORDER; PRIMARY PREVENTION; PSYCHOSES, SUBSTANCE-INDUCED; RETROSPECTIVE STUDIES; TRAVEL;

EID: 14544297026     PISSN: 00306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Barrett, P. J., Emmins, P. D., Clarke, P. D. és mtsa: Comparison of adverse events associated with use of mefloquine and combination chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ, 1996, 313, 525-528.
2. Bálint G.: A malária kemoprofilaxis jelenlegi lehetoségei. Orv. Hetil., 1994, 135, 241-243.
3. Croft, A., Garner, P.: Mefloquine to prevent malaria: a systematic review of trials: BMJ, 1997, 315, 1412-1416.
4. Croft, A. M., Herxheimer, A.: Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement? BMC Public Health, 2002, 2, 6.
5. Lobel, H. O., Miani, M., Eng, T. és mtsai: Long-term malaria prophylaxis with weekly mefloquine. Lancet, 1993, 341, 848-851.
6. Meszaros, K., Kasper, S.: Psychopathologische Phanomene im Langzeitverlauf einer akuten Psychose nach Mefloquinprophylaxe (Lariam). Nervenarzt, 1996, 67, 404-406.
7. Reid, A. J., Whitty, C. J., Ayles, H. M. és mtsai: Malaria at Christmas: risk of prophylaxis versus risk of malaria. BMJ, 1998, 317, 1506-1508.
8. Schlagenhauf, P.: Mefloquine for malaria chemoprphylaxis 1992-1998: a review. J. Travel Med., 1999, 6, 122-133.
9. Steffen, R., Fuchs, E., Schildknecht, J. és mtsai: Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet, 1993, 341, 1299-1303.
10. Torrey, E. F.: Chloroquine seizures. JAMA, 1968, 204, 867-871
11. Weinke, T., Trautmann, M., Held, T. és mtsai: Neuropsychiatric side effects after the use of mefloquine. Am. J. Trop. Hyg., 1991, 45, 86-91.
12. White, N. J.: Mefloquine. BMJ, 1994, 308, 286-287.
13. Wooltron, E: Mefloquine: contraindicated in patients with mood, psychotic or seizure disorders. Can. Med. Assoc. J., 2002, 167, 1147.
14. World Health Organisation: World malaria situation in 1994. WHO Wkly Epidemiol. Rec., 1997, 72, 269-274.
15. World Health Organisation: International Travel and Health. WHO, Geneve, 2002, 132-148. old.
16. Zubin, J., Spring, B.: Vulnerability- a new view of schizophrenia. J. Abnorm. Psychol., 1977, 86, 103-126
17. Zubin, J., Magaziner, J., Steinhauer, S. R.: The metamorphosis of schizophrenia: from chronicity to vulnerability. Psychol. Med., 1983, 13, 551-571.